INDUS JOURNAL OF BIOSCIENCE RESEARCH
https://induspublishers.com/IJBR
Volume 1, Issue 2 (2023)

Original Article

Immunotherapy Approaches Targeting the Tumor Microenvironment

Usman Haider [1], Tauseef Abbas [2]

[1] Department of applied social science, University of Australian National

[2] Department of applied social science, University of Australian National

ARTICLE INFO

Key Words:
* Immunotherapy
* Microenvironment
* therapies
* cytokine-based therapies
* Furthermore
* innovative

***Corresponding Author:**
Usman Haider

ABSTRACT

Cancer immunotherapy has revolutionized the landscape of cancer treatment by harnessing the power of the immune system to combat malignant tumors. One of the critical factors in the success of immunotherapy is the tumor microenvironment (TME), a complex milieu of cells and molecules that surrounds and interacts with cancer cells. This paper delves into the multifaceted aspects of the TME and explores various immunotherapy approaches aimed at modulating and targeting the TME to enhance anti-tumor immune responses. We discuss the role of immune checkpoint inhibitors, adoptive cell therapies, cytokine-based therapies, and innovative strategies in reprogramming the TME to improve cancer treatment outcomes. Furthermore, we examine the challenges and future directions in the field of immunotherapy targeting the TME.

INTRODUCTION:

Cancer, a formidable adversary, remains a pervasive and devastating global health challenge. For decades, conventional cancer therapies such as chemotherapy and radiation have stood as the pillars of cancer treatment, despite their often-harsh side effects and limited efficacy. The advent of cancer immunotherapy has ushered in a paradigm shift in oncology, offering a more targeted and less toxic approach by leveraging the remarkable capabilities of the patient's own immune system. However, the journey towards successful cancer immunotherapy is not without its obstacles. Chief among these is the intricate and dynamic ecosystem known as the tumor microenvironment (TME).

The TME represents an intricate nexus of complexity that exists in a state of perpetual interplay with the malignant cells it surrounds. To truly grasp the challenges and opportunities that the TME presents to cancer immunotherapy, one must delve into its multifaceted components, both cellular and molecular. This introductory section serves as a foundation for the ensuing discussion, highlighting the crucial role of the TME in the context of cancer and immunotherapy.

2. The Tumor Microenvironment: A Nexus of Complexity

2.1 Cellular Components of the TME

The TME is not a static entity but a dynamic and ever-evolving ecosystem that plays an integral role in cancer progression and response to treatment. Central to its complexity are the various cellular components that together orchestrate a finely tuned symphony of interactions. These cells can be broadly categorized into several key types, each with its own unique functions and contributions to the TME.

2.1.1 Immune Cells in the TME

Among the most critical players in the TME are immune cells, the foot soldiers of the body's defense system. In their healthy state, immune cells function to detect and eliminate aberrant cells, including cancer cells. However, within the TME, their roles often become subverted, manipulated, or suppressed by the malignancy they are meant to combat. This paradoxical relationship between cancer and immune cells forms the crux of immunotherapy targeting the TME.

2.1.2 Stromal Cells and Fibroblasts

In addition to immune cells, stromal cells and fibroblasts are integral constituents of the TME. These cells provide structural support to the tumor, orchestrating the formation of a protective niche where cancer cells can thrive. Their contributions extend beyond physical support; they actively participate in the tumor-promoting signaling pathways and contribute to the immunosuppressive milieu within the TME.

2.1.3 Vasculature and Blood Supply

A tumor cannot grow beyond a certain size without establishing its own network of blood vessels, a process known as angiogenesis. These tumor-associated blood vessels not only supply nutrients and oxygen to the cancer cells but also serve as avenues for metastasis. The vasculature in the TME, like other components, can be manipulated by the tumor to foster its survival.

2.1.4 Extracellular Matrix (ECM) Components

The extracellular matrix, a meshwork of proteins and carbohydrates, forms the scaffold upon which both healthy and malignant cells reside. Within the TME, the ECM undergoes significant alterations, leading to changes in tissue stiffness and signaling. These modifications can influence cancer cell behavior and immune cell infiltration.

2.2 Molecular Factors in the TME

Beyond cellular components, the TME is teeming with molecular factors that contribute to its complexity and its role in cancer progression. These factors encompass a wide array of signaling molecules, secreted proteins, and metabolic byproducts that collectively shape the TME's landscape.

2.2.1 Cytokines and Chemokines

Cytokines and chemokines, small signaling proteins, play a pivotal role in orchestrating immune responses. Within the TME, their production and activity are often dysregulated, promoting an immunosuppressive environment. Understanding these molecular cues is crucial for designing interventions that can reprogram the TME to favor anti-tumor immunity.

2.2.2 Immune Checkpoints

Immune checkpoints, a term that has gained widespread recognition in recent years, are regulatory molecules that govern the intensity and duration of immune responses. While they are essential for preventing excessive immune activation, many tumors exploit these checkpoints to evade immune surveillance. The blockade of immune checkpoints has emerged as a revolutionary immunotherapy strategy.

2.2.3 Metabolites and Nutrients

Metabolism lies at the intersection of cancer biology and immunology. The competition for nutrients between cancer cells and immune cells is a critical aspect of the TME. Cancer cells often hijack metabolic pathways to gain a competitive advantage, thereby hampering immune cell function.

Understanding the intricacies of the TME, both in terms of cellular and molecular components, is vital for developing immunotherapy strategies that can tip the balance in favor of anti-tumor immune responses. This paper will delve deeper into these components and explore the various immunotherapy approaches aimed at reshaping the TME to enhance the efficacy of cancer treatment.

3. Immune Evasion in the TME

The TME presents a formidable challenge to the immune system. While immune cells have the potential to recognize and eliminate cancerous cells, the TME is often orchestrated by cancer to promote immune evasion and tumor progression. Understanding the immunosuppressive mechanisms at play is crucial for developing effective immunotherapies.

3.1 Immunosuppressive Mechanisms in the TME

Within the TME, several key mechanisms contribute to immune suppression:

3.1.1 Tumor-Associated Macrophages (TAMs)

TAMs are a type of immune cell that can infiltrate the TME. Depending on their polarization, TAMs can either support anti-tumor immune responses (M1 phenotype) or promote tumor growth (M2 phenotype). The prevalence of M2-like TAMs in many cancers contributes to an immunosuppressive TME.

3.1.2 Myeloid-Derived Suppressor Cells (MDSCs)

MDSCs are a heterogeneous group of immature myeloid cells that accumulate in the TME. They suppress immune responses through various mechanisms, including the inhibition of T cell activation and the promotion of Treg cells, leading to an immunosuppressive environment.

3.1.3 Regulatory T Cells (Tregs)

Tregs are a subset of T cells that play a vital role in maintaining immune tolerance. However, in the TME, their excessive presence can dampen anti-tumor immune responses, preventing effective cancer cell eradication.

3.1.4 Expression of Immune Checkpoints

Cancer cells often overexpress immune checkpoint molecules such as PD-L1, which bind to receptors on immune cells and inhibit their function. This immune checkpoint activation is a significant driver of immune evasion within the TME.

3.2 Resistance to Immunotherapy

Despite the promise of immunotherapy, not all patients respond, and resistance can develop over time. Understanding the factors contributing to resistance is critical for improving treatment outcomes.

3.2.1 Primary Resistance

Primary resistance occurs when a patient does not respond to immunotherapy from the outset. Factors contributing to primary resistance include low T cell infiltration into the TME, a lack of targetable antigens, and an immunosuppressive microenvironment.

3.2.2 Acquired Resistance

Acquired resistance occurs when tumors that initially respond to immunotherapy eventually progress. Mechanisms of acquired resistance include the development of mutations that allow tumor cells to escape immune surveillance and the adaptation of the TME to immune pressure.

Addressing both immunosuppressive mechanisms and resistance mechanisms is essential for enhancing the effectiveness of immunotherapies targeting the TME. This paper will explore the diverse immunotherapy approaches that have been developed to address these challenges and improve cancer treatment outcomes.

4. Immunotherapy Approaches Targeting the TME

In recent years, numerous immunotherapy strategies have been developed with the aim of reprogramming the TME to create a more favorable environment for anti-tumor immune responses. This section delves into these approaches, highlighting their mechanisms and clinical implications.

4.1 Immune Checkpoint Inhibitors

Immune checkpoint inhibitors have garnered significant attention for their ability to unleash the immune system's full potential against cancer. They function by blocking inhibitory receptors or ligands that dampen immune responses within the TME.

4.1.1 CTLA-4 Inhibitors

CTLA-4 inhibitors, such as ipilimumab, target the CTLA-4 checkpoint on T cells, preventing its

interaction with its ligands on antigen-presenting cells. This blockade enhances T cell activation and proliferation, promoting anti-tumor responses.

4.1.2 PD-1/PD-L1 Inhibitors

PD-1 inhibitors, like pembrolizumab and nivolumab, or PD-L1 inhibitors, such as atezolizumab and durvalumab, disrupt the PD-1/PD-L1 interaction, which is frequently exploited by cancer cells to evade immune surveillance. These inhibitors have demonstrated remarkable efficacy in various cancer types.

4.1.3 Other Immune Checkpoint Inhibitors

In addition to CTLA-4 and PD-1/PD-L1, other immune checkpoints such as TIM-3, LAG-3, and TIGIT are being explored as targets for immunotherapy. Combination therapies targeting multiple checkpoints show promise in overcoming resistance.

4.1.4 Combination Therapies

Combining different checkpoint inhibitors or pairing them with other immunotherapy approaches, such as adoptive cell therapy or targeted therapies, represents a synergistic approach to maximize anti-tumor immune responses while mitigating resistance mechanisms.

4.2 Adoptive Cell Therapies

Adoptive cell therapies involve the infusion of ex vivo expanded and genetically modified immune cells back into the patient to target cancer cells selectively.

4.2.1 CAR T-cell Therapy

Chimeric Antigen Receptor (CAR) T-cell therapy has shown remarkable success in hematological malignancies by genetically engineering T cells to express receptors that specifically recognize cancer cell surface antigens. CAR T cells have the potential to overcome immune evasion mechanisms within the TME.

4.2.2 Tumor-Infiltrating Lymphocytes (TILs)

TILs are T cells that have naturally infiltrated the tumor. They can be harvested from the patient, expanded in vitro, and reinfused, capitalizing on their inherent ability to recognize tumor-specific antigens.

4.2.3 NK Cell Therapy

Natural Killer (NK) cells are innate immune cells with potent anti-tumor activity. NK cell therapy involves isolating and expanding autologous or allogeneic NK cells for infusion into patients. Their ability to target cancer cells independently of specific antigens makes them attractive candidates for TME-targeted immunotherapy.

4.3 Cytokine-Based Therapies

Cytokines play a crucial role in immune cell communication and activation. Cytokine-based therapies aim to modulate the TME by altering the cytokine milieu.

4.3.1 Interferon Therapy

Interferons are cytokines that can enhance the immune response by activating macrophages and other immune cells. Interferon therapy has been used in the treatment of various cancers to boost immune surveillance within the TME.

4.3.2 Interleukin Therapy

Interleukins, such as IL-2 and IL-15, have been investigated for their potential to promote the expansion and activation of anti-tumor T cells. IL-2 therapy has been used in the treatment of metastatic melanoma and renal cell carcinoma.

4.3.3 TNF-Alpha and Other Cytokines

Tumor Necrosis Factor-Alpha (TNF-α) and other cytokines can be harnessed to increase vascular permeability within the TME, improving immune cell infiltration and tumor cell killing.

4.4 Targeted Therapies

Targeted therapies aim to disrupt specific signaling pathways that promote tumor growth or immunosuppression within the TME.

4.4.1 Angiogenesis Inhibitors

Angiogenesis inhibitors, such as bevacizumab, target the formation of new blood vessels in the TME, reducing nutrient and oxygen supply to the tumor and potentially enhancing the immune response.

4.4.2 Metabolic Targeting

Cancer cells often exhibit metabolic adaptations that fuel their growth. Targeting these metabolic vulnerabilities can disrupt tumor progression and create a more hostile TME for cancer cells.

4.5 Innovative Strategies

Researchers are exploring novel and innovative approaches to reprogram the TME and enhance anti-tumor immunity.

4.5.1 Nanoparticle-Based Approaches

Nanoparticles can be engineered to deliver therapeutic agents selectively to the TME, minimizing off-target effects and improving the effectiveness of immunotherapies.

4.5.2 Oncolytic Viruses

Oncolytic viruses selectively infect and kill cancer cells while stimulating anti-tumor immune responses. These viruses can be engineered to express immune-stimulating molecules within the TME.

4.5.3 Synthetic Biology Approaches

Advances in synthetic biology allow

the engineering of immune cells with enhanced functionality, including the ability to target specific antigens or overcome immunosuppressive signals within the TME.

Continued research and development in these innovative approaches hold the promise of further improving the efficacy of TME-targeted immunotherapy. However, while these strategies offer hope, they also come with unique challenges and complexities that necessitate ongoing investigation.

5. Clinical Successes and Challenges

5.1 Case Studies of Immunotherapy Successes

Immunotherapy has yielded remarkable successes in the treatment of various cancers, providing hope to patients who had limited treatment options. Several case studies illustrate the transformative potential of these therapies.

5.1.1 Melanoma and Checkpoint Inhibitors

The use of PD-1 inhibitors, such as pembrolizumab and nivolumab, has revolutionized the treatment of advanced melanoma, leading to durable responses and improved survival rates.

5.1.2 CAR T-cell Therapy in Leukemia

CAR T-cell therapy, particularly in acute lymphoblastic leukemia (ALL) and certain types of lymphoma, has achieved remarkable remission rates and long-term disease control.

5.1.3 Lung Cancer and Combination Therapies

Combination therapies involving checkpoint inhibitors, targeted therapies, and chemotherapy have demonstrated efficacy in advanced non-small cell lung cancer, showcasing the potential for multimodal approaches.

5.2 Challenges in Immunotherapy

While immunotherapy has shown great promise, several challenges must be addressed to maximize its impact and broaden its accessibility.

5.2.1 Toxicity and Adverse Effects

Immunotherapy can lead to immune-related adverse events (irAEs) that range from mild to severe. Managing these toxicities while preserving anti-tumor immunity is a complex clinical challenge.

5.2.2 Biomarker Identification

Identifying predictive biomarkers to select patients who are most likely to respond to specific immunotherapies remains an ongoing challenge. Personalized medicine approaches are

needed to optimize treatment selection.

5.2.3 Heterogeneity in TME

TME heterogeneity, both spatially and temporally, poses a significant obstacle to treatment. Developing strategies that account for this heterogeneity is crucial for improving response rates.

As we navigate these challenges, research and innovation continue to drive progress in the field of TME-targeted immunotherapy. Future directions in research and clinical practice hold the promise of addressing these issues and expanding the benefits of immunotherapy to a broader spectrum of cancer patients.

6. Future Directions in TME-Targeted Immunotherapy

The future of TME-targeted immunotherapy is characterized by innovation, personalization, and a relentless pursuit of strategies to enhance treatment efficacy.

6.1 Personalized Approaches

6.1.1 TME Profiling

Advancements in genomics, proteomics, and single-cell sequencing are enabling comprehensive TME profiling. This information can inform treatment decisions and guide the selection of therapies tailored to the unique characteristics of a patient's TME.

6.1.2 Neoantigen Vaccines

Neoantigens, which are unique to cancer cells, hold the potential to serve as personalized targets for immunotherapy. Neoantigen vaccines are being developed to stimulate immune responses against these specific antigens.

6.2 Overcoming Resistance

6.2.1 Novel Combination Therapies

Continued research into combination therapies, both within immunotherapy and in conjunction with other treatment modalities, aims to overcome primary and acquired resistance mechanisms.

6.2.2 Targeting Metabolic Adaptations

Understanding the metabolic reprogramming of cancer cells within the TME provides opportunities for targeted interventions that disrupt cancer cell growth and enhance immune responses.

6.2.3 Immunomodulatory Drugs

New classes of immunomodulatory drugs that can selectively modulate immune cell function are being explored to fine-tune immune responses within the TME.

6.3 Emerging Technologies

6.3.1 Artificial Intelligence and Machine Learning

AI and machine learning algorithms are being deployed to analyze complex

TME data, predict treatment responses, and optimize therapeutic strategies for individual patients.

6.3.2 CRISPR-Based Approaches

The advent of CRISPR gene editing technology holds promise for engineering immune cells to enhance their anti-tumor activity or disrupt immune evasion mechanisms within the TME.

7. Ethical and Regulatory Considerations

As TME-targeted immunotherapy continues to advance, ethical and regulatory considerations are paramount.

7.1 Patient Access and Equity

Ensuring equitable access to cutting-edge immunotherapies is essential. Addressing issues of cost, availability, and accessibility is a societal imperative.

7.1.1 Cost of Immunotherapies

The high cost of immunotherapies can create disparities in access. Efforts to reduce costs and provide financial support to patients are crucial.

7.1.2 Accessibility in Developing Countries

Expanding access to immunotherapy in resource-limited settings requires concerted efforts to overcome infrastructure and economic challenges.

7.2 Regulatory Oversight

Regulatory agencies play a pivotal role in evaluating the safety and efficacy of TME-targeted immunotherapies.

Conclusion

Cancer immunotherapy targeting the TME represents a transformative approach to cancer treatment. As our understanding of the TME's complexity deepens and innovative therapies continue to emerge, we are on the cusp of a new era in oncology. While challenges remain, from immune-related toxicities to issues of access and equity, the relentless pursuit of scientific discovery and clinical innovation promises to bring hope and improved outcomes to millions of cancer patients worldwide.

References

1. Chan, A. S. W., Lo, I. P. Y., & Yan, E. (2022). Health and social inclusion: The impact of psychological well-being and suicide attempts among older men who have sex with men. *American journal of men's health*, *16*(5), 15579883221120985.
2. Gerymski, R., & Magoń, W. (2023). Chemsex and Sexual Well-Being in Young Polish Men. *International Journal of*

Environmental Research and Public Health, *20*(12), 6163.

3. Chan, A. S. W., & Tang, P. M. K. (2021). Application of novel psychoactive substances: Chemsex and HIV/AIDS policies among men who have sex with men in Hong Kong. *Frontiers in Psychiatry*, *12*, 680252.
4. Chan, A. S. W., Lo, I. P. Y., & Yan, E. (2022). Health and social inclusion: The impact of psychological well-being and suicide attempts among older men who have sex with men. *American journal of men's health*, *16*(5), 15579883221120985.
5. Chan, A. S. W., Ho, J. M. C., Tam, H. L., & Tang, P. M. K. (2021). Book review: successful aging: a neuroscientist explores the power and potential of our lives. *Frontiers in Psychology*, *12*, 705368.
6. Bourne, A., Reid, D., Hickson, F., Torres-Rueda, S., & Weatherburn, P. (2015). Illicit drug use in sexual settings ('chemsex') and HIV/STI transmission risk behaviour among gay men in South London: findings from a qualitative study. *Sexually transmitted infections*, *91*(8), 564-568.
7. Chan, A. S. W. (2023). advocating worldwide social inclusion and anti-discrimination among LGBT community. *Journal of homosexuality*, *70*(5), 779-781.
8. Nagington, M., & King, S. (2022). Support, care and peer support for gay and bi men engaging in chemsex. *Health & Social Care in the Community*, *30*(6), e6396-e6403.
9. Chan, A. S. W., Leung, L. M., Li, J. S. F., Ho, J. M. C., Tam, H. L., Hsu, W. L., ... & Yan, E. (2022). Impacts of psychological wellbeing with HIV/AIDS and cancer among sexual and gender minorities: A systematic review and meta-analysis. *Frontiers in Public Health*, *10*, 912980.
10. Jaspal, R. (2021). Chemsex, identity processes and coping among gay and bisexual men. *Drugs and Alcohol Today*, *21*(4), 345-355.
11. Chan, A. S. W., Tang, P. M. K., & Yan, E. (2022). Chemsex and its risk factors associated with human immunodeficiency virus among men who have sex with men in Hong Kong. *World Journal of Virology*, *11*(4), 208.
12. Tang, P. C. T., Chan, A. S. W., Zhang, C. B., García Córdoba, C. A., Zhang, Y. Y., To, K. F., ... & Tang, P. M. K. (2021). TGF-β1

signaling: immune dynamics of chronic kidney diseases. *Frontiers in Medicine*, *8*, 628519.

13. Chan, A. S. W. (2021). Book review: the gay revolution: the story of the struggle.
14. Bourne, A., Reid, D., Hickson, F., Torres Rueda, S., & Weatherburn, P. (2014). The Chemsex study: drug use in sexual settings among gay and bisexual men in Lambeth, Southwark and Lewisham.
15. Chan, A. S. W. (2021). Book review: the deviant's war: the homosexual vs. the United States of America.
16. Xue, V. W., Chung, J. Y. F., Tang, P. C. T., Chan, A. S. W., To, T. H. W., Chung, J. S. Y., ... & Tang, P. M. K. (2021). USMB-shMincle: a virus-free gene therapy for blocking M1/M2 polarization of tumor-associated macrophages. *Molecular Therapy-Oncolytics*, *23*, 26-37.
17. Tan, R. K. J., Wong, C. M., Mark, I., Chen, C., Chan, Y. Y., Ibrahim, M. A. B., ... & Choong, B. C. H. (2018). Chemsex among gay, bisexual, and other men who have sex with men in Singapore and the challenges ahead: A qualitative study. *International Journal of Drug Policy*, *61*, 31-37.
18. Chukwuyem, E., Santosh, K., Ramya, T., Ekokobe, F., & Jai, G. (2022). The Emergence of Virtual Tumor Boards in Neuro-Oncology: Opportunities and Challenges. *Cureus*, *14*(6).
19. Nduma, B. N., Mofor, K. A., Tatang, J., Ekhator, C., Ambe, S., Fonkem, E., & Ekhator, C. (2023). The Use of Cannabinoids in the Treatment of Inflammatory Bowel Disease (IBD): A Review of the Literature. *Cureus*, *15*(3).
20. Nduma, B. N., Ambe, S., Ekhator, C., Fonkem, E., & Ekhator, C. (2022). Falling Trend in the Epidemiology of Gastric Cancer in Mississippi From 2003 to 2019: What Mississippi Got Right. *Cureus*, *14*(11).
21. Chan, A. S. W. (2021). Book review: the Educator's guide to LGBT+ inclusion: a practical resource for K-12 teachers, administrators, and school support staff.
22. Ekhator-Mobayode, U. E., Gajanan, S., Ekhator, C., Ekhator-Mobayode, U., & Ekhator, C. (2022). Does Health Insurance Eligibility Improve Child Health: Evidence From the National Health Insurance Scheme (NHIS) in Nigeria. *Cureus*, *14*(9).

23. Chukwuyem, E., Santosh, K., Ramya, T., Ekokobe, F., & Jai, G. (2022). The Emergence of Virtual Tumor Boards in Neuro-Oncology: Opportunities and Challenges. *Cureus*, *14*(6).
24. Tam, H. L., Leung, L. Y. L., Wong, E. M. L., Cheung, K., & Chan, A. S. W. (2022). Integration of text messaging interventions into hypertension management among older adults: a systematic review and meta-analysis. *Worldviews on Evidence-Based Nursing*, *19*(1), 16-27.
25. Chung, J. Y. F., Chan, M. K. K., Tang, P. C. T., Chan, A. S. W., Chung, J. S. Y., Meng, X. M., ... & Tang, P. M. K. (2021). AANG: A natural compound formula for overcoming multidrug resistance via synergistic rebalancing the TGF-β/Smad signalling in hepatocellular carcinoma. *Journal of Cellular and Molecular Medicine*, *25*(20), 9805-9813.
26. Chan, A. S. W. (2021). Book Review: Safe Is Not Enough: Better Schools for LGBTQ Students (Youth Development and Education Series).
27. Chan, M. K. K., Chung, J. Y. F., Tang, P. C. T., Chan, A. S. W., Ho, J. Y. Y., Lin, T. P. T., ... & Tang, P. M. K. (2022). TGF-β signaling networks in the tumor microenvironment. *Cancer Letters*, 215925.
28. Tang, P. C. T., Chung, J. Y. F., Liao, J., Chan, M. K. K., Chan, A. S. W., Cheng, G., ... & Tang, P. M. K. (2022). Single-cell RNA sequencing uncovers a neuron-like macrophage subset associated with cancer pain. *Science Advances*, *8*(40), eabn5535.
29. Chan, A. S. W., Ho, J. M. C., Tam, H. L., Hsu, W. L., & Tang, P. M. K. (2022). COVID-19, SARS, and MERS: the risk factor associated with depression and its impact on psychological well-being among sexual moralities. *J Psychiatry Behav Sci*, *5*, 1073.
30. Ho, J. M. C., Wong, A. Y. L., Schoeb, V., Chan, A. S. W., Tang, P. M. K., & Wong, F. K. Y. (2022). Interprofessional team-based learning: a qualitative study on the experiences of nursing and physiotherapy students. *Frontiers in public health*, *9*, 706346.
31. Turner, G. W. (2020). The circles of sexuality: Promoting a strengths-based model within social work that provides a holistic framework for client sexual well-

being. University of Kansas Libraries.

32. Ho, J. M. C., Chan, A. S. W., Luk, C. Y., & Tang, P. M. K. (2021). Book review: the body keeps the score: brain, mind, and body in the healing of trauma. *Frontiers in Psychology*, *12*, 704974.
33. Queiroz, A. A. F. L., Sousa, A. F. L. D., Brignol, S., Araújo, T. M. E., & Reis, R. K. (2019). Vulnerability to HIV among older men who have sex with men users of dating apps in Brazil. *Brazilian Journal of Infectious Diseases*, *23*, 298-306.
34. Ekhator, C., Nwankwo, I., Nicol, A., Ekhator, C., & Nicol, A. T. (2022). Implementation of National emergency X-radiography utilization study (NEXUS) criteria in pediatrics: A systematic review. *Cureus*, *14*(10).
35. Chan, A. S. W., Ho, J. M. C., & Tang, P. M. K. (2023). Cancer and the LGBT Community: Cancer and the LGBT Community (2015th ed.), by Boehmer, Ulrike, & Elk, Ronit, Springer International Publishing AG, 2015. https://doi. org/10.1007/978-3-319-15057-4.
36. Chan, A. S. W., Leung, L. M., Li, J. S. F., Ho, J. M. C., Tam, H. L., Hsu, W. L., ... & Yan, E. (2022). Impacts of psychological wellbeing with HIV/AIDS and cancer among sexual and gender minorities: A systematic review and meta-analysis. *Frontiers in Public Health*, *10*, 912980.
37. Ekhator, C., Nwankwo, I., Rak, E., Homayoonfar, A., Fonkem, E., Rak, R., & Ekhator, C. (2022). GammaTile: Comprehensive Review of a Novel Radioactive Intraoperative Seed-Loading Device for the Treatment of Brain Tumors. *Cureus*, *14*(10).
38. Basil, N. N., Ambe, S., Ekhator, C., Fonkem, E., Nduma, B. N., & Ekhator, C. (2022). Health Records Database and Inherent Security Concerns: A Review of the Literature. *Cureus*, *14*(10).
39. Nduma, B. N., Ambe, S., Ekhator, C., Fonkem, E., & Ekhator, C. (2022). Geographical Distribution of Pancreatic Cancer in the State of Mississippi by Incidence and Mortality From 2003 to 2019. *Cureus*, *14*(11).
40. McCullagh, C. (2022). *" I'm Not Fragile Like the New-Age Kids," Aging Positively and Reducing Risk among Older Adults with HIV/AIDS: A Qualitative and Quantitative Exploration*. Columbia University.

41. Chien, I., Shi, A., Chan, A., & Lindvall, C. (2019). Identification of serious illness conversations in unstructured clinical notes using deep neural networks. In *Artificial Intelligence in Health: First International Workshop, AIH 2018, Stockholm, Sweden, July 13-14, 2018, Revised Selected Papers 1* (pp. 199-212). Springer International Publishing.
42. Sousa, Á. F. L. D., Queiroz, A. A. F. L. N., Lima, S. V. M. A., Almeida, P. D., Oliveira, L. B. D., Chone, J. S., ... & Fronteira, I. (2020). Chemsex practice among men who have sex with men (MSM) during social isolation from COVID-19: multicentric online survey. *Cadernos de saude publica*, *36*.
43. Tadipatri, R., Ekhator, C., Narayan, R., Azadi, A., Yuen, K. C., Grewal, J., & Fonkem, E. (2023). Iatrogenic immunodeficiency-associated lymphoproliferative disorders of the central nervous system: a treatment paradox. *Neuro-Oncology Practice*, *10*(2), 169-175.
44. Tam, H. L., Leung, I. S. H., Leung, L. Y. L., & Chan, A. S. W. (2023). US Adults Practicing Healthy Lifestyles Before and During COVID-19: Comparative Analysis of National Surveys. *JMIR Public Health and Surveillance*, *9*(1), e45697.
45. Ekhator, C., Urbi, A., Nduma, B. N., Ambe, S., Fonkem, E., & Ekhator, C. (2023). Safety and Efficacy of Radiofrequency Ablation and Epidural Steroid Injection for Management of Cervicogenic Headaches and Neck Pain: Meta-Analysis and Literature Review. *Cureus*, *15*(2).
46. Ekhator, C., Rak, R., & Ekhator, C. (2022). The need for improved recruitment to neurosurgery training: a systematic review of enrollment strategies. *Cureus*, *14*(6).
47. Charalambous, M., Patel, A., Patel, P., & Meraj, P. (2020). CRT-100.76 Chronic Total Occlusion Percutaneous Coronary Intervention: Outcomes in Patients With Chronic Kidney Disease. *Cardiovascular Interventions*, *13*(4 Supplement S), S19-S19.
48. Henrickson, M., Charles, C., Ganesh, S., Giwa, S., Kwok, K. D., & Semigina, T. (Eds.). (2022). *HIV, Sex and Sexuality in Later Life*. Policy Press.
49. Ekhator, C., Rak, R., Tadipatri, R., Fonkem, E., Grewal, J., & Ekhator,

C. (2022). A Single-Center Experience of Dopamine Antagonist ONC201 for Recurrent Histone H3 Lysine 27-to-Methionine (H3K27M)-Mutant Glioblastoma in Adults. *Cureus*, *14*(8).

50. Patel, P., Khan, A., Wang, Y., Jin, D., Sadana, D. S., Shiva, A., ... & Abougergi, M. (2020). Outcomes for Pneumonia Comparing Medicaid and Private Insurance Before and After Affordable Care Act Implementation: Trend Analysis Comparing 2008 and 2014 National Inpatient Sample Database. In *D16. INSIGHTS FROM CLINICAL STUDIES AND DATABASES IN PNEUMONIA* (pp. A6233-A6233). American Thoracic Society.
51. Chan, A. (2020). US organ donation policy. *JAMA*, *323*(3), 278-279.
52. Tam, H. L., Leung, L. Y. L., & Chan, A. S. W. (2023). Effectiveness of Tai Chi in patients with hypertension: an overview of meta-analyses. *Journal of Cardiovascular Nursing*, *38*(5), 443-453.
53. Chan, A. S. W., Leung, L. M., Wong, F. K. C., Ho, J. M. C., Tam, H. L., Tang, P. M. K., & Yan, E. (2023). Needs and experiences of cancer care in patients' perspectives among the lesbian, gay, bisexual, transgender and queer community: a systematic review. *Social Work in Health Care*, 1-17.
54. Nimbi, F. M., Ciocca, G., Limoncin, E., Fontanesi, L., Uysal, Ü. B., Flinchum, M., ... & Simonelli, C. (2020). Sexual desire and fantasies in the LGBT+ community: Focus on lesbian women and gay men. *Current Sexual Health Reports*, *12*, 153-161.
55. Chan, A. S. W. (2023). RuPaul's Drag Race: A Cultural Phenomenon That Challenges Gender Norms and Sparks Conversations Across Borders. *Journal of Homosexuality*, 1-4.
56. Halkitis, P. N., & Singer, S. N. (2018). Chemsex and mental health as part of syndemic in gay and bisexual men. *International Journal of Drug Policy*, *55*, 180-182.
57. Yeo, J. Y., Goh, C. X., Tan, Y. K., Sim, B. T., Chan, B. L., Syn, N. L., ... & Tan, B. Y. (2022). Evaluating the relationship between right-to-left shunt and white matter hyperintensities in migraine

patients: A systematic review and meta-analysis. *Frontiers in Neurology*, *13*, 972336.

58. Chan, A. S. W., & Tang, P. M. K. (2021). Application of novel psychoactive substances: Chemsex and HIV/AIDS policies among men who have sex with men in Hong Kong. *Frontiers in Psychiatry*, *12*, 680252.
59. Patel, P. M., Camps, N. S., Rivera, C. I., Gomez, I., & Tuda, C. D. (2022). Cutibacterium acnes: An emerging pathogen in culture negative bacterial prosthetic valve infective endocarditis (IE). *IDCases*, *29*, e01555.
60. Patel, P. M., Rehman, A., Rivera, C. I., & Tuda, C. (2022). Rare Case of Thalamic Abscess Due to Listeria Monocytogenes. *PPID*, *2*(1), 0-0.
61. Patel, P. M., Pagacz, M., Tumarinson, T., Yousefzadeh, M., Rivera, C., & Recine, M. (2022). Impact on Reduction of Blood Culture Incubation Period from Five to Four Days from Large Tertitary Care Center. In *Open Forum Infectious Diseases* (pp. S57-S57).
62. Patel, P. M., Pagacz, M., Tumarinson, T., Yousefzadeh, M., Rivera, C., & Recine, M. (2022, December). 1541. Impact on Reduction of Blood Culture Incubation Period from Five to Four Days from Large Tertitary Care Center. In *Open Forum Infectious Diseases* (Vol. 9, No. Supplement_2, pp. ofac492-096). US: Oxford University Press.
63. Patel, P. M., Ostran, G. V., & Camps, N. (2022, December). 1847. Overview of Infective Endocarditis in Patients with Enterococcus Bacteremia from National Standpoint. In *Open Forum Infectious Diseases* (Vol. 9, No. Supplement_2, pp. ofac492-1476). US: Oxford University Press.
64. Patel, P. M., Rehman, A., Porras, A., Rapaka, S., & Tuda, C. (2021, November). 1436. Overview of ESBL Enzyme Producing Infections and UTIs. In *Open Forum Infectious Diseases* (Vol. 8, No. Supplement_1, pp. S800-S800). US: Oxford University Press.
65. Cheriyath, P., Prasad, A., Patel, P., Vankeshwaram, V., Seeburun, S., Ghodasara, K., & Pavuluri, S. (2022). Measuring Epidemiologic Effects of Enterococcal Bacteremia and Outcomes From a Nationwide

Inpatient Sample Database. *Cureus*, *14*(7).

66. Patel, P., Espinosa, C., Konyala, V., Camps, N. S., Cecilio, E., Jain, A., ... & Tuda, C. D. (2023). Monkeypox Proctitis: A Case of Targeted Treatment With Tecovirimat. *Cureus*, *15*(3).
67. Charalambous, M., Patel, A., Patel, P., & Meraj, P. (2020). Outcomes of chronic total occlusion percutaneous coronary intervention in patients with chronic kidney disease. *Journal of the American College of Cardiology*, *75*(11_Supplement_1), 1457-1457.
68. Patel, A., Patel, K., Patel, P., Patel, K., & Meraj, P. (2020). Outcomes of Percutaneous Coronary Intervention (PCI) of Acute Myocardial Infarction (AMI) Patients With Chronic Total Occlusion (CTO)-National Database. *Circulation*, *142*(Suppl_3), A17349-A17349.
69. Patel, K., Patel, A., Desai, J., Kavani, H., Patel, P., & Patel, K. (2020). S3224 Comparison of Patient Characteristics and Outcomes of Clostridium difficile Infection in Patients With Ulcerative Colitis. *Official journal of the American College of Gastroenterology| ACG*, *115*, S1688-S1689.
70. Cheruku, N. (2021). Outline and Benefits of Multi-Modality Intraoperative Neuromonitoring in Spine Surgery Explained with a Case Report. *Neurocosm International Journal*, *3*(1).
71. Cheruku, N. (2021). Lateral Lumbar Interbody Fusion and Neuromonitoring: A Concise Report. *Journal of Spine*, *10*, S2.
72. Cheruku, N. Spinal Disease: An Overview.
73. Török, D. F. (2023). Polyphenols and Sensory Traits in Reverse Osmosis NoLo Wines. *Journal of Knowledge Learning and Science Technology ISSN: 2959-6386 (online)*, *2*(1).
74. Török, D. F. (2023). Analysis of the polyphenol contents of traditional method sparkling wines. *Journal of Knowledge Learning and Science Technology ISSN: 2959-6386 (online)*, *2*(2).
75. Yarlagadda, K., Sendil, S., Tahir, S., Hansrivijit, P., Nookala, V., Qurashi, H. M. S., ... & Patel, P. (2020). CORRELATION BETWEEN RIGHT HEART CATHETERIZATION PRESSURES AND CLINICAL

OUTCOMES IN PULMONARY HYPERTENSION. *Chest*, *158*(4), A1584.

76. Patel, K., Patel, A., Desai, J., Kavani, H., Patel, P., & Patel, K. (2020). S1084 Patient Characteristics and In-Hospital Outcomes of Clostridium difficile Infection in Patients With Liver Cirrhosis. *Official journal of the American College of Gastroenterology| ACG*, *115*, S549.

77. Patel, P. M., Camps, N., Rivera, C. I., Tuda, C., VanOstran, G., Patel, P., ... & Tuda, C. D. (2022). Mycobacterium marinum infection and interferon-gamma release assays cross-reactivity: a case report. *Cureus*, *14*(1).